Replies to post #610966 on NorthWest Biotherapeutics Inc (NWBO)

[skitahoe]

Thanks Umibe,

Of course some of that is Greek to me, but I get the idea. I've been big about mentioning T-Cells because I don't believe they were previously mentioned in the Jama Journal, I believe the clinicians determined what occurred during the trial, the recent presentations told us more about the why, and the added benefits of adding other therapeutics, which weren't a part of the Phase 3 Trial.

Gary

[Doc logic]

Umibe5690,

Great post. Remember also that methylation status allows for more or less speed towards tumor reparation and recovery and mesenchymal signature is mostly unmethylated so getting L to these patients more quickly will likely make a significant difference in overall effect. Therefore, manufacturing and product release time can be considered patient specific critical especially since chemo is generally not beneficial to unmethylated MGMT patients. Regulators have lots to think about with this treatment platform, safety not being part of it. Best wishes.